Reports
Reports
Sale
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Trends | Impact |
Technological Advancements | Innovations in vector technology including capsid modification for reduced immunogenicity and improved tissue specificity, are expanding the therapeutic potential of AAV vectors. The increasing enhancements in vector design are important for increasing the precision of therapies to target specific tissues, thereby reducing off-target effects, and improving outcomes. Also, the advancements improve safety profile and expands the applicability to a broader range of diseases. |
Increasing Investments in Gene Therapy Companies | Pharmaceutical investments and venture capital is growing in gene therapy startups and major companies focuses on AAV vectors. This financial support not only boosts the scale of ongoing projects but also flourishes the emergence of innovative treatment modalities which has the potential to revolutionize the healthcare. |
Expansion into Chronic and Multifactorial Diseases | With the initial focus on monogenic diseases, AAV vector-based gene therapy is increasingly being explored for the treatment of multifactorial and chronic diseases like Alzheimer’s, Parkinson’s, and heart diseases. This strategic shift not only diversifies the applications of gene therapy but also has the potential to impact a larger patient population, significantly broadening the market. |
Growing Regulatory Support | The regulatory agencies like the FDA and EMA, are crucial in reducing the time for new treatments to arrive in the market. They are also vital in streamlining the process of approval for gene therapies. Special designations such as 'orphan drug' status and 'fast track' approvals are increasingly granted to AAV-based therapies, particularly those targeting rare and life-threatening diseases. Potentially leading to a surge in innovative treatments for complex diseases. |
Adeno-Associated Virus Vector-Based Gene Therapy Market Size
Adeno-Associated Virus Vector-Based Gene Therapy Market Growth
Adeno-Associated Virus Vector-Based Gene Therapy Market Trends
Adeno-Associated Virus Vector-Based Gene Therapy Market Share
Adeno-Associated Virus Vector-Based Gene Therapy Market Regional Analysis
Adeno-Associated Virus Vector-Based Gene Therapy Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Overview
3.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Historical Value (2017-2023)
3.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Forecast Value (2024-2032)
4 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Landscape*
4.1 Global Adeno-Associated Virus Vector-Based Gene Therapy: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Adeno-Associated Virus Vector-Based Gene Therapy: Product Landscape
4.2.1 Analysis by Therapeutic Application
4.2.2 Analysis by Application
5 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentation (2017-2032)
6.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
6.1.1 Market Overview
6.1.2 Neurological Disorders
6.1.3 Ophthalmic Disorders
6.1.4 Muscular Disorders
6.1.5 Hematological Disorders
6.1.6 Metabolic Disorders
6.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
6.2.1 Market Overview
6.2.2 Rare Diseases
6.2.3 Cancer
6.2.4 Inherited Genetic Disorders
6.3 Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals and Clinics
6.3.3 Research Institutes and Universities
6.3.4 Biotechnology and Pharmaceutical Companies
6.4 Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
7.1 North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
7.1.1 Market Overview
7.1.2 Neurological Disorders
7.1.3 Ophthalmic Disorders
7.1.4 Muscular Disorders
7.1.5 Hematological Disorders
7.1.6 Metabolic Disorders
7.2 North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
7.2.1 Market Overview
7.2.2 Rare Diseases
7.2.3 Cancer
7.2.4 Inherited Genetic Disorders
7.3 North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
8.1 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
8.1.1 Market Overview
8.1.2 Neurological Disorders
8.1.3 Ophthalmic Disorders
8.1.4 Muscular Disorders
8.1.5 Hematological Disorders
8.1.6 Metabolic Disorders
8.2 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
8.2.1 Market Overview
8.2.2 Rare Diseases
8.2.3 Cancer
8.2.4 Inherited Genetic Disorders
8.3 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
9.1 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
9.1.1 Market Overview
9.1.2 Neurological Disorders
9.1.3 Ophthalmic Disorders
9.1.4 Muscular Disorders
9.1.5 Hematological Disorders
9.1.6 Metabolic Disorders
9.2 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
9.2.1 Market Overview
9.2.2 Rare Diseases
9.2.3 Cancer
9.2.4 Inherited Genetic Disorders
9.3 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
10.1 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
10.1.1 Market Overview
10.1.2 Neurological Disorders
10.1.3 Ophthalmic Disorders
10.1.4 Muscular Disorders
10.1.5 Hematological Disorders
10.1.6 Metabolic Disorders
10.2 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
10.2.1 Market Overview
10.2.2 Rare Diseases
10.2.3 Cancer
10.2.4 Inherited Genetic Disorders
10.3 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
11.1 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
11.1.1 Market Overview
11.1.2 Neurological Disorders
11.1.3 Ophthalmic Disorders
11.1.4 Muscular Disorders
11.1.5 Hematological Disorders
11.1.6 Metabolic Disorders
11.2 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
11.2.1 Market Overview
11.2.2 Rare Diseases
11.2.3 Cancer
11.2.4 Inherited Genetic Disorders
11.3 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share by Top 5 Companies
17.2 Arya Sciences Acquisition Corp.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 BioMarin Pharmaceutical Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bayer AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Coave Therapeutics
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 MeiraGTx Limited
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Neurocrine Biosciences, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Biogen, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications Mergers and Acquisitions
17.9.6 Certifications
17.10 Sangamo Therapeutics
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sarepta Therapeutics, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Global Adeno-Associated Virus Vector-Based Gene Therapy Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.